Phase 1 N=32 Safety and Blood Levels After a Single Injection of UPB-101 in Healthy Japanese and Non-Japanese Non-East Asian Adults
Healthy
Primary: Maximum Observed Concentration (Cmax) of UPB-101 — 11.6; 24.4; 35.1; 34.9 ug/mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=8 Study of Multiple Oral Doses of PF-06835919 in Healthy Adult Japanese Participants
Healthy
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs , and TEAEs Leading to Participant Discontinuation From Study — 0; 3; 0; 0…
Phase 1 N=56 A Study of LY110140 in Healthy Japanese Male Participants
Healthy Volunteer
Primary: Number of Participants With One or More Drug-Related Adverse Events (AEs) or Any Serious AEs During the Single-Dose (SD) Period — 0; 0; 0; 0 participants
Phase 1 N=24 Study of rhPTH(1-84) in Japanese Healthy Subjects Compared With Matched Caucasian Healthy Adult Subjects
Hypoparathyroidism
Primary: Baseline-adjusted Cmax of PTH(1-84) — 295.662; 330.820; 175.468; 99.708 Picogram per milliliter (pg/mL)
Phase 1 N=24 Phase 1 TAK-906 Single and Multiple Ascending Dose Study in Japanese Healthy Male Participants
Japanese Healthy Adult Male Participants
Primary: Number of Participants Who Experience at Least One Treatment-Emergent Adverse Event (TEAE) — 1; 0; 2; 1 Participants
Phase 4 N=160 Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Japanese Adults
SARS-CoV-2 Infection · COVID-19
Primary: Percentage of Participants With Local Reactions by Maximum Severity Within 7 Days After Dose 1 — 7.6; 0.0; 5.9; 0.0 Percentage of participants
Phase 1 N=27 A Study of Lasmiditan in Healthy Japanese and Caucasian Participants
Healthy
Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — 0; 0; 0; 0 Participants
Phase 1 N=48 This Study Tests BI 1467335 in Healthy Japanese and Caucasian Men. The Study Tests How Different Doses of BI 1467335 Are Taken up in the Body and How Well They Are Tolerated
Healthy
Primary: Percentage of Subjects With Drug-related Adverse Events — 22.2; 33.3; 0.0; 0.0 Percentage of subjects
Phase 1 N=36 A Study of LY3337641 in Japanese and Caucasian Healthy Participants
Healthy
Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — 0; 0; 0; 0 Participants
Phase 1 N=45 A Study of LY2951742 in Healthy Japanese and Caucasian Participants
Migraine Disorders
Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — 0; 0; 0; 0 Participants
Phase 1 N=50 A Study on the Reactogenicity, Safety and Immune Response of a Targeted Immunotherapy Against HSV in Healthy Japanese Participants Aged 18-40 Years
Herpes Simplex
Primary: Number of Participants Reporting Any Solicited Administration Site Events — 8; 2; 0; 19 Participants
Phase 2 N=107 A Healthy Volunteer Pharmacokinetics (PK)/Pharmacodynamics (PD), Safety and Tolerability Study of Andexanet in Healthy Japanese and Caucasian Subjects
Bleeding
Primary: Percent Change in Anti-Fxa Activity From Baseline to the End of Infusion (EOI) Nadir. — -94.50; -29.00; -98.00; -37.00 percent change — p=0.0275
Phase 1 N=12 Phase I Study of GSK2982772 in Japanese Healthy Male Participants
Autoimmune Diseases
Primary: Number of Participants Reporting Adverse Events (AEs) and Serious Adverse Events (SAEs) — 0; 1; 0; 0 Participants
Phase 1 N=39 A Study of LY2484595 in Healthy Subjects
Healthy Volunteers
Primary: Pharmacokinetics: Area Under the Plasma Concentration Versus Time Curve (AUC) of LY2484595 — 12200; 17800; 17800 hours times nanograms per milliliter
Phase 1 N=72 Safety, Tolerability and Pharmacokinetics of BI 1026706 in Healthy Chinese and Japanese Male Volunteers
Healthy
Primary: Percentage of Subjects With Drug-related Adverse Events (AEs) — 0.0; 0.0; 0.0; 5.6 Percentage of participants
Phase 2 N=55 A Phase 1/2 Study of a Intramuscular Injection of TAK-850 in Healthy Adult Subjects
Influenza
Primary: Number of Participants With Solicited Injection Site and Systemic Adverse Events — 1; 2; 1; 3 participants
Phase 1 N=16 TAK-648 Multiple-Rising Dose Study in Healthy Japanese Participants and Non-Japanese Participants With Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Primary: Percentage of Participants Who Have at Least 1 Treatment-Emergent Adverse Event (TEAE) for Part 1 — 83.3; 33.3; 100.0 percentage of participants
Phase 1 N=56 A Study in Healthy Japanese Men to Test How Different Doses of BI 1569912 Are Taken up by the Body and How Well They Are Tolerated
Healthy
Primary: SRD Part - Number of Subjects With Drug-related Adverse Events — 0; 0; 0; 0 Participants
Phase 2 N=48 An Electrophysiological Study Of E2014 In Healthy Adult Male Japanese And Caucasian Subjects
Spasmodic Torticollis
Primary: Maximum Rates of Extensor Digitorum Brevis (EDB) Muscle M-Wave Amplitude Reduction From Baseline — 9.02; 48.53; 70.95; 81.62 Percentage of Reduction
Phase 1 N=40 V710 Clinical Study in Healthy Male Japanese Subjects (V710-006) (COMPLETED)
Staphylococcal Infection
Primary: Geometric Mean Fold Rise (GMFR) From Baseline in Antibody Level — 4.4; 0.9 Ratio
Phase 1 N=9 Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of GSK2330811 in Healthy Japanese Participants
Healthy Volunteers
Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 2; 6; 0; 0 Participants
Phase 1 N=32 Single Rising Dose Trial of Spesolimab (BI 655130) for Healthy Japanese Male Subjects
Healthy
Primary: Number of Subjects With Drug-related Adverse Events (AEs) — 0; 0; 0; 0 Participants
Phase 2 N=200 A Study of TAK-019 in Healthy Japanese Adults (COVID-19)
Prevention of Infection Disease Caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)
Primary: Percentage of Participants With Solicited Local Adverse Events (AEs) for Six Subsequent Days Following First Vaccination — 4.0; 29.3; 4.0; 43.3 percentage of participants
Phase 1 N=95 PK Study of PT003 and PT001 in Japanese Healthy Subjects
COPD
Primary: Cmax — 15.23; 9.09; 16.85; 7.26 pg/mL
Phase 1 N=65 Safety, Tolerability and Pharmacokinetics of BI 409306 Tablets in Healthy Asian Male Volunteers
Healthy
Primary: Percentage (%) of Subjects With Drug-related Adverse Events (AEs) — 13.3; 9.1; 36.4; 57.9 Percentage of Participants
Phase 1 N=12 Open-label, Single-arm Study to Assess the Pharmacokinetics, Safety, and Tolerability of a Single Subcutaneous Dose of Icatibant in Healthy Japanese Volunteers
Hereditary Angioedema (HAE)
Primary: Peak Plasma Concentration (Cmax) of Icatibant and Metabolites — 1190; 340; 365 ng/mL
Phase 1 N=69 A Study of LY3015014 in Healthy Participants With Elevated Low Density Lipoprotein Cholesterol
Hyperlipidemia
Primary: Number of Participants With Clinically Significant Effects — 0; 0; 0; 0 Participants
Phase 1 N=49 Single Rising Dose Trial of BI 425809 for Healthy Japanese and Chinese Male Subjects
Healthy
Primary: Number of Subjects With Drug-Related Adverse Events (AEs) — 1; 0; 0; 0 Participants
Phase 1 N=105 Pharmacokinetics of BIA 9-1067 in Healthy Japanese and Caucasian Subjects
Parkinson Disease
Primary: Cmax of BIA 9-1067 - Maximum Observed Plasma Concentration of BIA 9-1067 (Day 1) — 182; 794; 1540; 176 ng/mL
Phase 2 N=200 A Study of TAK-919 in Healthy Japanese Adults (COVID-19)
Coronavirus Disease (COVID-19)
Primary: Percentage of Participants With Solicited Local Adverse Events (AEs) for Six Subsequent Days Following First Vaccination — 6.0; 82.7; 0.0; 2.0 percentage of participants